Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA168949
Max Phase: Preclinical
Molecular Formula: C22H30N6O4S
Molecular Weight: 474.59
Molecule Type: Small molecule
Associated Items:
ID: ALA168949
Max Phase: Preclinical
Molecular Formula: C22H30N6O4S
Molecular Weight: 474.59
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCc1nc(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nn12
Standard InChI: InChI=1S/C22H30N6O4S/c1-5-7-19-23-15(3)20-22(29)24-21(25-28(19)20)17-14-16(8-9-18(17)32-6-2)33(30,31)27-12-10-26(4)11-13-27/h8-9,14H,5-7,10-13H2,1-4H3,(H,24,25,29)
Standard InChI Key: AIVNVMRJLJHFCU-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 474.59 | Molecular Weight (Monoisotopic): 474.2049 | AlogP: 1.68 | #Rotatable Bonds: 7 |
Polar Surface Area: 112.90 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 10 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 8.93 | CX Basic pKa: 5.98 | CX LogP: 0.75 | CX LogD: 0.72 |
Aromatic Rings: 3 | Heavy Atoms: 33 | QED Weighted: 0.55 | Np Likeness Score: -1.58 |
1. Haning H, Niewöhner U, Schenke T, Es-Sayed M, Schmidt G, Lampe T, Bischoff E.. (2002) Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors., 12 (6): [PMID:11958981] [10.1016/s0960-894x(02)00030-6] |
2. Haning H, Niewöhner U, Schenke T, Lampe T, Hillisch A, Bischoff E.. (2005) Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors., 15 (17): [PMID:15993055] [10.1016/j.bmcl.2005.05.090] |
3. Antunes JE, Freitas MP, da Cunha EF, Ramalho TC, Rittner R.. (2008) In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil., 16 (16): [PMID:18656371] [10.1016/j.bmc.2008.07.022] |
4. Jansen C, Kooistra AJ, Kanev GK, Leurs R, de Esch IJ, de Graaf C.. (2016) PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design., 59 (15): [PMID:26908025] [10.1021/acs.jmedchem.5b01813] |
Source(1):